Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

As the process that silences gene expression ensues during development, the stage is set
for the activity of Polycomb-repressive complex 2 (PRC2) to maintain these repressed gene …

Versatile and precise genome modifications are needed to create a wider range of adoptive
cellular therapies,,,–. Here we report two improvements that increase the efficiency of …

Human induced pluripotent stem cells (iPSCs) provide a potentially unlimited resource for
cell therapies, but the derivation of mature cell types remains challenging. The histone …

The developmental origin of blood-forming hematopoietic stem cells (HSCs) is a
longstanding question. Here, our non-invasive genetic lineage tracing in mouse embryos …

T cells are pivotal effectors of the immune system and can be harnessed as therapeutics for
regenerative medicine and cancer immunotherapy. An unmet challenge in the field is the …

Polycomb Repressive Complex 2 (PRC2) exhibits key roles in mammalian development
through its temporospatial repression of gene expression. EZH1 or EZH2 is the catalytic …

Macrophages derived from human induced pluripotent stem cells (iPSCs) have the potential
to enable the development of cell-based therapies for numerous disease conditions. We …

Hematopoiesis is the process by which both fetal and adult organisms derive the full
repertoire of blood cells from a single multipotent progenitor cell type, the hematopoietic …

The maintenance of gene expression patterns during metazoan development is achieved, in
part, by the actions of polycomb repressive complex 2 (PRC2). PRC2 catalyzes mono-, di …